BIA
NVO

Bigelow Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bigelow Investment Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,084
Closed -$213K – 151
2025
Q2 		$213K Buy
3,084
+200
+7% +$13.6K 0.09% 145
2025
Q1 		$200K Buy
+2,884
New +$238K 0.1% 146
2024
Q4 		– Sell
-2,123
Closed -$253K – 153
2024
Q3 		$253K Buy
2,123
+118
+6% +$15.7K 0.11% 146
2024
Q2 		$286K Hold
2,005
– – 0.14% 134
2024
Q1 		$257K Buy
+2,005
New +$239K 0.13% 142
2023
Q1 		– Sell
-3,000
Closed -$203K – 150
2022
Q4 		$203K Buy
+3,000
New +$176K 0.12% 142

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bigelow Investment Advisors's NVO Position: Q3 2025 in Review

Bigelow Investment Advisors sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,084 shares — an estimated $213K sold.

Bigelow Investment Advisors first reported a position in NVO in Q4 2022 and held it in 6 quarters. The position peaked at $286K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Bigelow Investment Advisors reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Bigelow Investment Advisors sold 3,084 Novo Nordisk shares in Q3 2025, an estimated $213K.
  • Bigelow Investment Advisors first reported a position in Novo Nordisk in Q4 2022 and held it in 6 quarters.
  • Bigelow Investment Advisors's Novo Nordisk position peaked at $286K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Bigelow Investment Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.